Royalty Pharma plc
RPRXUS売上高
$2.4B
百万USD
営業利益
$1.6B
百万USD
純利益
$771M
百万USD
ROE
-
最新FY
EPS
$1.78
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $573M | $69M | $0.18 |
| FY2021 | Q2 | $555M | $441M | $1.08 |
| FY2021 | Q3 | $586M | $102M | $0.24 |
| FY2021 | FY | $2.3B | $620M | $1.49 |
| FY2022 | Q1 | $562M | $52M | $0.12 |
| FY2022 | Q2 | $536M | $305M | $0.70 |
| FY2022 | Q3 | $573M | $143M | $0.32 |
| FY2022 | FY | $2.2B | $43M | $0.10 |
| FY2023 | Q1 | $684M | $341M | $0.76 |
| FY2023 | Q2 | $538M | $228M | $0.50 |
| FY2023 | Q3 | $536M | $72M | $0.16 |
| FY2023 | FY | $2.4B | $1.1B | $2.53 |
| FY2024 | Q1 | $568M | $5M | $0.01 |
| FY2024 | Q2 | $537M | $102M | $0.23 |
| FY2024 | Q3 | $565M | $544M | $1.21 |
| FY2024 | FY | $2.3B | $859M | $1.91 |
| FY2025 | Q1 | $568M | $238M | $0.55 |
| FY2025 | Q2 | $579M | $30M | $0.07 |
| FY2025 | Q3 | $609M | $288M | $0.67 |
| FY2025 | FY | $2.4B | $771M | $1.78 |
| FY2026 | Q1 | $631M | $295M | $0.67 |
財務データ
| 指標 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| 売上高 | $2.1B | $2.3B | $2.2B | $2.4B | $2.3B | $2.4B |
| 営業利益 | $1.6B | $1.4B | $307M | $1.5B | $1.3B | $1.6B |
| 純利益 | $975M | $620M | $43M | $1.1B | $859M | $771M |
| 総資産 | $16.0B | $17.5B | $16.8B | $16.4B | $18.2B | $19.6B |
| 純資産 | $9.9B | $10.2B | $9.5B | $10.1B | $10.3B | $9.7B |
| 自己資本 | - | - | - | - | - | - |
| 営業CF | $2.0B | $2.0B | $2.1B | $3.0B | $2.8B | $2.5B |
| EPS | $1.32 | $1.49 | $0.10 | $2.53 | $1.91 | $1.78 |
| BPS | - | - | - | - | - | - |
| ROE | - | - | - | - | - | - |